摘要
目的研究脑胶质瘤组织中YTH结构域N6-甲基腺嘌呤RNA结合蛋白2(YTH domain N6-methyladenine RNA binding protein 2,YTHDF2),UBX结构域蛋白1(UBX domain protein 1,UBXN1)的表达及预后评估价值。方法选取2017年2月~2018年2月青岛市胶州中心医院诊治的92例脑胶质瘤患者。免疫组织化学检测组织YTHDF2,UBXN1表达。相关性采用Spearman秩相关分析。Kaplan-Meier曲线分析YTHDF2,UBXN1表达与脑胶质瘤患者预后的影响。COX分析脑胶质瘤患者预后影响因素。结果相比于癌旁组织,脑胶质瘤中YTHDF2(65.22%vs 15.22%)阳性率较高,UBXN1(26.09%vs 73.91%)的阳性率较低,差异具有统计学意义(χ^(2)=47.831,42.087,均P<0.05)。Spearman秩相关分析,脑胶质瘤中YTHDF2与UBXN1表达呈负相关(r=-0.712,P<0.05)。相比于肿瘤直径<3cm,WHO分级Ⅰ~Ⅱ级,肿瘤直径≥3cm和WHO分级Ⅲ级脑胶质瘤组织中YTHDF2(75.47%vs 51.28%,65.22%vs 50.00%)阳性率较高,而UBXN1(15.09%vs 41.03%,11.11%vs 47.37%)阳性率较低,差异具有统计学意义(χ^(2)=5.795,6.609;7.835,15.207,均P<0.05)。YTHDF2阳性组五年总生存率低于阴性组[28.33%(17/60)vs 62.50%(20/32)],UBXN1阳性组五年总生存率高于阴性组[66.67%(16/24)vs 30.88%(21/68)],差异具有统计学意义(Log-Rankχ^(2)=12.870,7.665,均P<0.05)。YTHDF2阳性(HR=2.427,95%CI:1.426~4.569)、UBXN1阴性(HR=1.740,95%CI:1.121~2.568)、WHO分级Ⅲ级(HR=2.671,95%CI:1.160~6.012)及肿瘤直径≥3cm(HR=1.628,95%CI:1.017~2.592)是胶质瘤患者不良预后的危险因素。结论脑胶质瘤组织中YTHDF2升高,UBXN1降低,两者与WHO分级及肿瘤直径有关。YTHDF2和UBXN1是评估脑胶质瘤患者预后的独立因素。
Objective This study aims to investigate the expression of YTH domain N6-methyladenine RNA binding protein 2(YTHDF2)and UBX domain protein 1(UBXN1)in glioma tissue and their prognostic value.Methods A total of 92 glioma cases that underwent surgical treatment in Qingdao Jiaozhou Central Hospital from February 2017 to February 2018 were included.Immunohistochemistry was used to detect YTHDF2 and UBXN1 expression.Spearman rank correlation analysis was conducted.Kaplan-Meier survival curves were plotted to analyze the association between YTHDF2,UBXN1 expression and prognosis in glioma patients.COX analysis was used to determine the prognostic factors affecting glioma patients.Results Compared with adjacent tissues,the positivity rate of YTHDF2(65.22%vs 15.22%)was significantly higher in gliomas,while the positivity rate of UBXN1(26.09%vs 73.91%)was lower,and differences were statistically significant(χ^(2)=47.831,42.087,all P<0.05).Spearman rank correlation analysis,showed a negative correlation between YTHDF2 and UBXN1 expression in gliomas(r=-0.712,P<0.05).Compared with tumors diameter<3cm and WHO grades I to II,YTHDF2(75.47%vs 51.28%,65.22%vs 50.00%)had a higher positivity rate in glioma tissues with tumor diameter≥3cm and WHO gradeⅢ,while UBXN1(15.09%vs 41.03%,11.11%vs 47.37%)had a lower positivity rate,and differences were statistically significant(χ^(2)=5.795,6.609;7.835,15.207,all P<0.05).The five-year overall survival rate of YTHDF2 positive group was lower than that of negative group[28.33%(17/60)vs 62.50%(20/32)],while thefive-year overall survival rate of UBXN1 positive group was higher than that of negative group[66.67%(16/24)vs 30.88%(21/68)],and the differences were statistically significant(Log-Rankχ^(2)=12.870,7.665,all P<0.05).YTHDF2 positive(HR=2.427,95%CI:1.426~4.569),UBXN1 negative(HR=1.740,95%CI:1.121~2.568),WHO grade III(HR=2.671,95%CI:1.160~6.012)and tumor diameter≥3cm(HR=1.628,95%CI:1.017~2.592)were risk factors for poor survival prognosis in glioma patients.Conclusion YTHDF2 increas
作者
史明旭
宫晶
李小伟
SHI Mingxu;GONG Jing;LI Xiaowei(Department of Neurosurgery,Qingdao Jiaozhou Central Hospital,Qingdao 266300,China;Department of Paediatrics,Qingdao Jiaozhou Central Hospital,Qingdao 266300,China)
出处
《现代检验医学杂志》
CAS
2024年第6期130-134,210,共6页
Journal of Modern Laboratory Medicine
基金
山东省医药卫生科技发展计划项目(202014050419)。
